Saptalis Pharmaceuticals announced the commercial launch of cyclosporine ophthalmic emulsion 0.05%, a generic version of Restasis (Abbvie), for the treatment of dry eye disease.
The preservative-free, single-use formulation, which is available in 30-count and 60-count single-use vials, is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
In addition to the ophthalmic launch, Saptalis announced the approval and commercialization of several new products spanning autoimmune disorders, psychiatry, dermatology, and allergy-related conditions:
- Tofacitinib Oral Solution, 1 mg/mL (240 mL), indicated for the treatment of autoimmune and inflammatory conditions, including rheumatoid arthritis and related disorders.
- Hydroxyzine HCl Oral Solution, USP 10 mg/5 mL (473 mL), indicated for the symptomatic relief of anxiety and tension, as well as the management of pruritus associated with allergic conditions.
- Chlorpromazine HCl Oral Concentrate, 30 mg/mL (120 mL) and 100 mg/mL (240 mL), indicated for the treatment of schizophrenia and other psychotic disorders and for the control of severe nausea and vomiting.
- Desoximetasone Cream, USP 0.05% and 0.25% (15 g and 60 g), indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
- Fluocinonide Topical Solution, USP 0.05% (20 mL and 60 mL), indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive scalp and skin conditions.
All products are available by prescription. For full prescribing information, visit www.saptalis.com.
